SPRINT BIOSCIENCE AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.27 SEK | -8.63% |
|
-4.80% | -26.80% |
| 05-08 | Sprint Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 02-14 | Sprint Bioscience AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 150.6 | 162.9 | 191.1 | 22.03 | 121.1 | 97.05 | - | - |
| Enterprise Value (EV) 1 | 150.6 | 135.9 | 120.4 | -7.459 | 71.2 | 26.05 | -51.95 | 97.05 |
| P/E ratio | -6.35 x | -3.01 x | -5.64 x | - | - | - | - | - |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 4.49 x | 9.65 x | 5.44 x | 265 x | 2.4 x | 1.01 x | 0.47 x | 0.6 x |
| EV / Revenue | 4.49 x | 8.05 x | 3.43 x | -89.9 x | 1.41 x | 0.27 x | -0.25 x | 0.6 x |
| EV / EBITDA | - | -3.66 x | -4.81 x | 0.12 x | -179 x | 1.24 x | -0.39 x | 1.16 x |
| EV / FCF | - | -3.31 x | -2.81 x | 0.13 x | -4.05 x | 1.24 x | -0.67 x | 1.37 x |
| FCF Yield | - | -30.2% | -35.6% | 792% | -24.7% | 80.6% | -150% | 73.2% |
| Price to Book | - | 17.8 x | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 12,343 | 21,215 | 39,844 | 39,844 | 69,820 | 69,820 | - | - |
| Reference price 2 | 12.20 | 7.680 | 4.795 | 0.5530 | 1.735 | 1.390 | 1.390 | 1.390 |
| Announcement Date | 19/02/20 | 17/02/21 | 16/02/22 | 15/02/23 | 14/02/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 33.54 | 16.88 | 35.11 | 0.083 | 50.48 | 96 | 208 | 163 |
| EBITDA 1 | - | -37.15 | -25.04 | -60.12 | -0.398 | 21 | 133 | 84 |
| EBIT 1 | - | -37.85 | -25.63 | -60.74 | -0.845 | 20 | 132 | 83 |
| Operating Margin | - | -224.15% | -72.99% | -73,180.72% | -1.67% | 20.83% | 63.46% | 50.92% |
| Earnings before Tax (EBT) | - | -42.79 | -25.08 | - | - | - | - | - |
| Net income | - | -42.79 | -25.08 | - | - | - | - | - |
| Net margin | - | -253.43% | -71.43% | - | - | - | - | - |
| EPS | -1.920 | -2.550 | -0.8500 | - | - | - | - | - |
| Free Cash Flow 1 | - | -41.05 | -42.82 | -59.05 | -17.59 | 21 | 78 | 71 |
| FCF margin | - | -243.1% | -121.96% | -71,149.4% | -34.85% | 21.88% | 37.5% | 43.56% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 100% | 58.65% | 84.52% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 19/02/20 | 17/02/21 | 16/02/22 | 15/02/23 | 14/02/24 | - | - | - |
1SEK in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 |
|---|---|---|
| Net sales | - | - |
| EBITDA 1 | - | -5.052 |
| EBIT 1 | - | -5.142 |
| Operating Margin | - | - |
| Earnings before Tax (EBT) | - | - |
| Net income | 28.62 | - |
| Net margin | - | - |
| EPS | 0.4100 | - |
| Dividend per Share | - | - |
| Announcement Date | 25/10/23 | 14/02/24 |
1SEK in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 27.1 | 70.6 | 29.5 | 49.9 | 71 | 149 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -41 | -42.8 | -59.1 | -17.6 | 21 | 78 | 71 |
| ROE (net income / shareholders' equity) | - | -425% | -63% | -122% | -1.57% | 54% | 104% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | 0.4300 | - | - | - | - | - | - |
| Cash Flow per Share | - | -2.450 | - | - | - | - | - | - |
| Capex 1 | - | - | 2.71 | - | 2.45 | 1 | 2 | 2 |
| Capex / Sales | - | - | 7.71% | - | 4.86% | 1.04% | 0.96% | 1.23% |
| Announcement Date | 19/02/20 | 17/02/21 | 16/02/22 | 15/02/23 | 14/02/24 | - | - | - |
1SEK in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -26.80% | 9.07M | |
| +8.63% | 114B | |
| +13.17% | 107B | |
| -12.76% | 22.22B | |
| -2.45% | 21.28B | |
| -7.19% | 17.51B | |
| -39.93% | 17.17B | |
| +6.67% | 14.14B | |
| +33.90% | 12.2B | |
| -28.60% | 7.83B |
- Stock Market
- Equities
- SPRINT Stock
- Financials Sprint Bioscience AB
